Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy

Cancer Genetics and Cytogenetics

Volumn 182, Issue 2, 2008, Pages 95-102

  Richebourg, Steven ^a   Eclache, Virginie ^b   Perot, Christine ^c   Portnoi, Marie France ^d   Van den Akker, Jacqueline ^d   Terré, Christine ^e   Maareck, Odile ^f   Soenen, Valérie ^a   Viguié, Franck ^g   Laï, Jean Luc ^a   Andrieux, Joris ^a   Corm, Sélim ^a   Roche Lestienne, Catherine ^a,h  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e Center for Blood Transfusion   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ABL1 GENE; ARTICLE; BCR GENE; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MOLECULAR GENETICS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

CYTOGENETIC ANALYSIS; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 41749098088     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.01.005     Document Type: Article

References (29)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 34 (1999) 164-172
2. Shtivelman E., Lifshitz B., Gale R.P., and Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315 (1985) 550-554
3. Huret J.L. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet 85 (1990) 565-568
4. Babicka L., Zemanova Z., Pavlistova L., Brezinova J., Ransdorfova S., Houskova L., Moravcova J., Klamova H., and Michalova K. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 168 (2006) 22-29
5. Fitzgerald P.H., and Morris C.M. Complex chromosomal translocations in the Philadelphia chromosome leukemias: serial translocations or a concerted genomic rearrangement?. Cancer Genet Cytogenet 57 (1991) 143-151
6. Reid A.G., Huntly B.J., Grace C., Green A.R., and Nacheva E.P. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 121 (2003) 419-427
7. Naumann S., and Decker H.J. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet 147 (2003) 18-22
8. Gorusu M., Benn P., Li Z., and Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 173 (2007) 97-106
9. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
10. Huntly B.J., Reid A.G., Bench A., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
11. Storlazzi C.T., Specchia G., Anelli L., Albano F., Pastore D., Zagaria A., Rocchi M., and Liso V. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35 (2002) 271-276
12. Specchia G., Albano F., Anelli L., Storlazzi C.T., Pastore D., Zagaria A., Rocchi M., and Liso V. Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. Leuk Lymphoma 45 (2004) 689-694
13. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
14. Morel F., Ka C., Le Bris M.J., Herry A., Morice P., Bourquard P., Abgrall J.F., Berthou C., and De Braekeleer M. Deletion of the 5′ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis. Leuk Lymphoma 44 (2003) 1333-1338
15. Fournier M., Lacrosse S., Jamar M., Bours V., and Herens C. Deletions of the 3′BCR and 5′ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells. Cancer Genet Cytogenet 160 (2005) 184-187
16. Lee D.S., Lee Y.S., Yun Y.S., Kim Y.R., Jeong S.S., Lee Y.K., She C.J., Yoon S.S., Shin H.R., Kim Y., and Cho H.I. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer 37 (2003) 291-299
17. Rudduck-Sivaswaren C., Tien S.L., Lim P., Lim E., Lie D.K., Tan P.H., and Lee A.S. Evidence for deletion of 9q as a two-step process in chronic myeloid leukemia. Clin Genet 68 (2005) 461-465
18. ISCN 1995: an international system for human cytogenetic nomenclature (1995). In: Mitelman F. (Ed) (1995), S. Karger, Basel
19. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R., and European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
20. Fitzgerald P.H. Complex Ph translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 55 (1991) 129-131
21. Nacheva E., Holloway T., Brown K., Bloxham D., and Green A.R. Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 87 (1994) 409-412
22. Ishihara T., and Minamihisamatsu M. The Philadelphia chromosome: considerations based on studies of variant Ph translocations. Cancer Genet Cytogenet 32 (1988) 75-92
23. Valle L., Fernández V., Pérez-Pons C., Sánchez F.G., Benítez J., and Urioste M. Generation of the BCR/ABL fusion gene in a Philadelphia chromosome-negative chronic myeloid leukaemia: insertion of 5.6 Mb of 9q34 into the BCR region of chromosome 22. Hematol Oncol 24 (2006) 86-88
24. Reddy K.S., and Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genet Cytogenet 118 (2000) 121-131
25. Lessard M., Duval S., and Fritz A. Unusual translocation and chronic myelocytic leukemia: "masked" Philadelphia chromosome (Ph 1). Cancer Genet Cytogenet 4 (1981) 237-244
26. Kim Y.R., Cho H.I., Yoon S.S., Park S., Kim B.K., Lee Y.K., Chun H., Kim H.C., and Lee D.S. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH. Genes Chromosomes Cancer 43 (2005) 37-44
27. Reid A.G., and Nacheva E.P. Genesis of derivative chromosome 9 deletions in chronic myeloid leukemia. Genes Chromosomes Cancer 43 (2005) 223-224
28. Aoun P., Wiggins M., Pickering D., Foran J., Rasheed H., Pavletic S.Z., and Sanger W. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 154 (2004) 138-143
29. Yehuda O., Abeliovich D., Ben-Neriah S., Sverdlin I., Cohen R., Varadi G., Orr R., Ashkenazi Y.J., Heyd J., Lugassy G., and Ben Yehuda D. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet 114 (1999) 100-107